Stocks · News reference
Filed: 2026-10-29 AccNo: 0001104659-26-120279 Size: 197 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Acurx Pharmaceuticals has scheduled a conference call for November 12, 2026, to discuss its third-quarter 2026 financial results and provide a business update.
Acurx Pharmaceuticals published preclinical data in ASM Spectrum demonstrating that its oral DNA polymerase IIIC inhibitors exhibit in vivo activity and microbiome-sparing effects compared to linezolid.
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access